Novo Nordisk NYSE:NVO, the Danish pharmaceutical giant behind Wegovy and Ozempic, raised its full-year outlook on Wednesday, but that still wasn't enough to satisfy investors. The stock slid more than 4% in Copenhagen trading as Wall Street looked beyond the better guidance and focused on a familiar problem: the next wave of blockbuster drugs. Management now expects 2026 adjusted sales and operating profit to range from flat to down 6% at constant exchange rates, a clear improvement from its previous forecast of a 4% to 12% decline. The guidance got better, but confidence didn't.
The latest quarter showed the core business is still throwing punches. Adjusted sales climbed 7% at constant exchange rates to DKK78.49 billion, while adjusted operating profit rose 11% to DKK33.39 billion. The oral Wegovy launch is gaining traction, with weekly U.S. prescriptions topping 265,000 by mid-July and cumulative prescriptions already exceeding five million. Then came the reality check. Novo booked DKK6.3 billion in noncash pipeline impairments, including DKK4 billion tied to monlunabant, while its ZEUS cardiovascular trial failed to hit its primary endpoint. Those disappointments stole the spotlight from another quarter of solid commercial execution.
The upgraded outlook narrowed the expected decline in both sales and operating profit from a midpoint of negative 8% to roughly negative 3%, but investors wanted more than better math. Reuters pointed to growing concerns over Novo's drug pipeline and intensifying competition from Eli Lilly NYSE:LLY, whose GLP-1 franchise continues to pull ahead. Wegovy and Ozempic remain cash-printing machines, but the market is already looking past today's winners and asking what comes next. Until Novo proves it has another blockbuster waiting in the wings, every pipeline setback is likely to carry outsized weight.
The GuruFocus chart screams one thing: expectations have collapsed. At $45.13, Novo Nordisk trades about 67.6% below its GF Value estimate of $139.24. That's an unusually wide discount for one of the world's premier pharmaceutical companies. Investors have stopped rewarding yesterday's blockbuster drugs and are demanding proof that the next generation is coming. Until Novo delivers that proof, the stock may stay under pressurebut if management executes, the valuation leaves meaningful room for a rerating.